Shares of Kodiak Sciences traded more than 100% higher at times after the company reported that it entered into a $225 million royalty agreement for the firm's KSI-301 used in the treatment of retinal vascular diseases including age-related macular degeneration and diabetic eye diseases.
This morning, clinical stage biopharmaceutical company Kodiak Sciences Inc. (KOD:NASDAQ), which specializes in developing novel therapeutics to treat chronic, high-prevalence retinal diseases, announced that "it has entered into a funding agreement to sell a capped royalty right on global net sales of KSI-301 to Baker Bros. Advisors for $225 million."
The company explains that KSI-301 is Kodiak's investigational therapy being developed for the treatment of retinal vascular diseases including age-related macular degeneration and diabetic eye diseases.
Under the terms of the agreement, Baker Bros. Advisors (BBA) purchased a capped 4.5% royalty on net sales of Kodiak's anti–vascular endothelial growth factor (anti-VEGF) medication. The royalty is to be paid upon marketing approval in exchange for $225 million in committed development funding payable to Kodiak Sciences. The report noted that the royalty "caps" or terminates when BBA has received an aggregate amount equal to 4.5 times the total funding amount paid to Kodiak.
According to the terms of the royalty agreement, BBA will pay Kodiak $100 million upon the closing of the funding transaction, which is expected to occur on January 10, 2020, with payment of the remaining $125 million predicated upon Kodiak achieving certain objectives. This includes, among other things, 50% enrollment in the firm's two planned pivotal clinical studies of KSI-301 in patients with retinal vein occlusion estimated to occur in late 2020.
Kodiak Sciences Chairman and CEO Victor Perlroth, MD, commented, "In thinking through how best to finance our accelerating clinical, manufacturing and commercial plans for KSI-301 and our ABC platform, royalty funding is meaningfully less dilutive than equity and preserves both our future financing and strategic flexibility...This royalty financing provides the foundation to fund the KSI-301 development program through our 2022 Vision of pivotal read-outs in retinal vein occlusion, wet age-related macular degeneration and diabetic macular edema and our anticipated Biologics License Application (BLA) and supplemental BLA submissions."
In the report, the firm identifies KSI-301 as an investigational anti-VEGF therapy built on the company's Antibody Biopolymer Conjugate (ABC) Platform designed to maintain potent and effective drug levels in ocular tissues for longer than existing agents. "Kodiak's objective with KSI-301 is to develop a new first-line agent to improve outcomes for patients with retinal vascular diseases and to enable earlier treatment and prevention of vision loss for patients with diabetic eye disease. The company's DAZZLE pivotal study in patients with treatment-naïve wet AMD was initiated in October 2019."
Kodiak Sciences is headquartered in Palo Alto, Calif., and describes its business as a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases. The firm states that "it has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, its bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and is expanding its early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and the neurodegenerative aspects of glaucoma."
Kodiak Sciences began the day with a market capitalization of about $1.1 billion with approximately 37.06 million shares outstanding and a short interest of around 7.40%. KOD shares opened almost 20% higher today at $35.00 (+$5.40, +18.24%) over Friday's $29.60 closing price, and then proceeded to take off setting a new 52-week intraday high price of $72.87. Since the open, the stock has traded between $35.00 to $72.87 per share and is presently trading at $48.72 (+$19.12, +64.59%).
Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.